Merck Q3 2024: GAAP EPS $1.24, Non-GAAP $1.57; Sales $16.7B (+4% YoY)

Merck & Co., Inc.

2024-Q3 EPS reported $5.26 revenue$48,544,000,000

Total worldwide sales $16.7B, up 4% (7% ex-FX). GAAP EPS $1.24; Non-GAAP EPS $1.57.
KEYTRUDA sales $7.4B (+17% / 21% ex-FX). WINREVAIR sales $149M, gaining momentum.
FY2024 guidance narrowed: sales $63.6B-$64.1B; Non-GAAP EPS $7.72-$7.77, includes $0.24/share net charge from Curon and Daiichi Sankyo deals.
R&D expenses surged 77% to $5.9B, driven by $1.35B EyeBio acquisition and $750M Curon asset purchase.
GARDASIL/GARDASIL 9 sales fell 11% due to lower China demand; Animal Health up 6% (11% ex-FX).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.